Arojojoye A, Awuah S
Coord Chem Rev. 2024; 522.
PMID: 39552640
PMC: 11563041.
DOI: 10.1016/j.ccr.2024.216208.
Bannwart F, Richter L, Stifel S, Rueter J, Lode H, Correia J
J Med Chem. 2024; 67(17):15494-15508.
PMID: 39196554
PMC: 11403678.
DOI: 10.1021/acs.jmedchem.4c01117.
Ding W, Cui Q, Lu W, Du Y, Luo Y, Hu Y
Front Chem. 2023; 11:1292115.
PMID: 38148758
PMC: 10750375.
DOI: 10.3389/fchem.2023.1292115.
Salmain M, Gaschard M, Baroud M, Lepeltier E, Jaouen G, Passirani C
Cancers (Basel). 2023; 15(18).
PMID: 37760418
PMC: 10526406.
DOI: 10.3390/cancers15184448.
Greif C, Mertens R, Berger G, Parkin S, Awuah S
RSC Chem Biol. 2023; 4(8):592-599.
PMID: 37547458
PMC: 10398352.
DOI: 10.1039/d3cb00051f.
Serum-Stable Gold(III) Bisphosphine Complex Induces Mild Mitochondrial Uncoupling and In Vivo Antitumor Potency in Triple Negative Breast Cancer.
Arojojoye A, Olelewe C, Gukathasan S, Kim J, Vekaria H, Parkin S
J Med Chem. 2023; 66(12):7868-7879.
PMID: 37279147
PMC: 10317555.
DOI: 10.1021/acs.jmedchem.3c00238.
Developing Bi-Gold Compound BGC2a to Target Mitochondria for the Elimination of Cancer Cells.
Cui Q, Ding W, Liu P, Luo B, Yang J, Lu W
Int J Mol Sci. 2022; 23(20).
PMID: 36293028
PMC: 9602679.
DOI: 10.3390/ijms232012169.
Revisiting the anticancer properties of phosphane(9-ribosylpurine-6-thiolato)gold(I) complexes and their 9H-purine precursors.
Kober L, Schleser S, Bar S, Schobert R
J Biol Inorg Chem. 2022; 27(8):731-745.
PMID: 36244017
PMC: 9653339.
DOI: 10.1007/s00775-022-01968-x.
Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials.
Kawano T, Inokuchi J, Eto M, Murata M, Kang J
Pharmaceutics. 2021; 13(11).
PMID: 34834162
PMC: 8621927.
DOI: 10.3390/pharmaceutics13111748.
Evaluating Ligand Modifications of the Titanocene and Auranofin Moieties for the Development of More Potent Anticancer Drugs.
Fernandez-Vega L, Ruiz Silva V, Dominguez-Gonzalez T, Claudio-Betancourt S, Toro-Maldonado R, Capre Maso L
Inorganics (Basel). 2021; 8(2).
PMID: 34046448
PMC: 8152503.
DOI: 10.3390/inorganics8020010.
Synthesis, Characterization, and Antiproliferative Activity of Novel Chiral [QuinoxP*AuCl] Complexes.
Arojojoye A, Mertens R, Ofori S, Parkin S, Awuah S
Molecules. 2020; 25(23).
PMID: 33291802
PMC: 7730091.
DOI: 10.3390/molecules25235735.
Repurposing Auranofin and Evaluation of a New Gold(I) Compound for the Search of Treatment of Human and Cattle Parasitic Diseases: From Protozoa to Helminth Infections.
Feng L, Pomel S, de Late P, Taravaud A, Loiseau P, Maes L
Molecules. 2020; 25(21).
PMID: 33139647
PMC: 7663263.
DOI: 10.3390/molecules25215075.
Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer.
Marzo T, Massai L, Pratesi A, Stefanini M, Cirri D, Magherini F
ACS Med Chem Lett. 2019; 10(4):656-660.
PMID: 30996813
PMC: 6466815.
DOI: 10.1021/acsmedchemlett.9b00007.
Auranofin Protects Intestine against Radiation Injury by Modulating p53/p21 Pathway and Radiosensitizes Human Colon Tumor.
Nag D, Bhanja P, Riha R, Sanchez-Guerrero G, Kimler B, Tsue T
Clin Cancer Res. 2019; 25(15):4791-4807.
PMID: 30940656
PMC: 9159899.
DOI: 10.1158/1078-0432.CCR-18-2751.
Dual targeting of the cancer antioxidant network with 1,4-naphthoquinone fused Gold(i) N-heterocyclic carbene complexes.
McCall R, Miles M, Lascuna P, Burney B, Patel Z, Sidoran K
Chem Sci. 2018; 8(9):5918-5929.
PMID: 29619196
PMC: 5859730.
DOI: 10.1039/c7sc02153d.
Auranofin, EtPAuCl, and EtPAuI Are Highly Cytotoxic on Colorectal Cancer Cells: A Chemical and Biological Study.
Marzo T, Cirri D, Gabbiani C, Gamberi T, Magherini F, Pratesi A
ACS Med Chem Lett. 2017; 8(10):997-1001.
PMID: 29057040
PMC: 5641946.
DOI: 10.1021/acsmedchemlett.7b00162.
N-Heterocyclic Carbene-Gold(I) Complexes Conjugated to a Leukemia-Specific DNA Aptamer for Targeted Drug Delivery.
Niu W, Chen X, Tan W, Veige A
Angew Chem Int Ed Engl. 2016; 55(31):8889-93.
PMID: 27311814
PMC: 5260866.
DOI: 10.1002/anie.201602702.
Gold(I) NHC-based homo- and heterobimetallic complexes: synthesis, characterization and evaluation as potential anticancer agents.
Bertrand B, Citta A, Franken I, Picquet M, Folda A, Scalcon V
J Biol Inorg Chem. 2015; 20(6):1005-20.
PMID: 26202908
DOI: 10.1007/s00775-015-1283-1.
Deubiquitinases (DUBs) and DUB inhibitors: a patent review.
Farshi P, Deshmukh R, Nwankwo J, Arkwright R, Cvek B, Liu J
Expert Opin Ther Pat. 2015; 25(10):1191-1208.
PMID: 26077642
PMC: 4834700.
DOI: 10.1517/13543776.2015.1056737.
A small molecule inhibitor of atypical protein kinase C signaling inhibits pancreatic cancer cell transformed growth and invasion.
Butler A, Scotti Buzhardt M, Erdogan E, Li S, Inman K, Fields A
Oncotarget. 2015; 6(17):15297-310.
PMID: 25915428
PMC: 4558152.
DOI: 10.18632/oncotarget.3812.